Company News & Press Releases

Media professionals who wish to learn more about Theraclone’s technology and areas of research and development, please contact us at:

media@theraclone-sciences.com
206.805.1600

Access recent company press releases via the links below. (Adobe Acrobat Required)

December 6, 2011 Theraclone Sciences Announces Appointment of Clifford Stocks as CEO
September 21, 2011 Theraclone Sciences Announces Initiation of Phase 1 Clinical Trial of TCN-032 for Influenza A
September 8, 2011 Theraclone Sciences Secures $10.6 Million in Series B Extension Financing
September 6, 2011 Theraclone Sciences Named a 2011 Fierce 15 Biotech by FierceBiotech
August 17, 2011 AIDS Researchers Isolate New Potent and Broadly Effective Antibodies Against HIV
January 19, 2011 Theraclone and Pfizer Enter into Infectious Disease and Cancer Antibody Discovery Collaboration
June 28, 2010 Theraclone Sciences Technology Uncovers Rare Anti-Influenza Antibodies
March 22, 2010 Zenyaku Kogyo Obtains Exclusive License in Japan to Theraclone's Influenza Monoclonal Antibody Program
October 4, 2009 Theraclone and Zenyaku Kogyo Announce Influenza Antibody Alliance
September 3, 2009 Two New Antibodies Found to Cripple HIV
July 6, 2009 IAVI and Theraclone Expand HIV Antibody Discovery Collaboration
March 30, 2009 Spaltudaq Corp. Announces Identification of Broadly and Potently Neutralizing Human HIV Antibodies and Change of Company Name to Theraclone Sciences, Inc.
March 16, 2007 Spaltudaq Corp Raises $29 Million: Second Accelerator Company to Complete Series B Financing
January 24, 2005 Spaltudaq Corp becomes third biotech company started by Accelerator
May 23, 2007 Spaltudaq Names New Senior Executives